Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31355073 | 1.00 | C5AR1 (0.33) | C5AR1ADAMTS5MAPTTACR1KMT2A | |
| SCHEMBL30510300 | 0.93 | TACR1 (0.36) | C5AR1ADAMTS5MAPTTACR1KMT2A | |
| SCHEMBL25183068 | 0.93 | TACR1 (0.36) | C5AR1ADAMTS5MAPTTACR1KMT2A | |
| SCHEMBL30510325 | 0.88 | PSEN1 (0.34) | MAPTKMT2APPARGPPARA | |
| SCHEMBL25179483 | 0.88 | PSEN1 (0.34) | MAPTKMT2APPARGPPARA | |
| SCHEMBL30510286 | 0.88 | GPR139 (0.35) | C5AR1PPARGPPARA | |
| SCHEMBL27078243 | 0.88 | GPR139 (0.35) | C5AR1PPARGPPARA | |
| SCHEMBL25182256 | 0.87 | PLA2G1B (0.39) | ADAMTS5 | |
| SCHEMBL30510319 | 0.87 | PLA2G1B (0.39) | ADAMTS5 | |
| SCHEMBL25185739 | 0.87 | CTSB (0.37) | MAPTPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | C5AR1 1047/4885ADAMTS5 3659/4885MAPT 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.